GlassScriptPhysician profile
Jeffrey M Williams
NPI 1124279328
$9,973.08
in general payments reported to CMS, 2019-2025
46 companies · $2,006 in 2025
The $2,006 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,796 · 2020: $748 · 2021: $1,003 · 2022: $978 · 2023: $1,743 · 2024: $1,698 · 2025: $2,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,447.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,640.00 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $1,327.44 | 2019-2025 | |
| Lilly USA, LLC | $910.52 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $868.22 | 2019-2025 | Farxiga, Airsupra, Bevespi Aerosphere |
| Abbvie INC. | $612.03 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Janssen Pharmaceuticals, INC | $566.81 | 2019-2025 | Xarelto, Spravato |
| Amgen INC. | $529.62 | 2019-2025 | Prolia, Evenity, Repatha |
| Glaxosmithkline, LLC. | $406.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $340.05 | 2019-2023 | Belsomra, Steglatro, Lagevrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.84 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $243.32 | 2019-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $221.65 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $210.49 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $164.93 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.73 | 2025 | Caplyta |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.